Neurodegenerative diseases remain one of drug development's toughest frontiers. Despite decades of research, disease-modifying therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions are still limited or nonexistent, and the path from encouraging preclinical data to regulatory approval is full of obstacles that demand operational excellence, not just scientific innovation.
Site selection is central to that equation. Poorly executed trials can compromise entire programs, while well-executed ones accelerate timelines and get treatments to patients faster. However, even as the trial site landscape shifts toward organized site networks, the network model alone does not guarantee the specialized expertise these trials require.
A high-stakes, high-complexity landscape
The regulatory and commercial environment for neurodegenerative disease therapies relies on exceptional research quality at every stage of development.
Regulatory scrutiny has intensified. High-profile debates over accelerated approvals, endpoint validity, and benefit-risk profiles mean sponsors must show not just statistical significance but clinically meaningful benefit using defensible, well-validated measures. For trials incorporating subjective cognitive or functional assessments, variability across sites can obscure real treatment effect and raise questions about rater consistency, reliability, and whether a given endpoint change is clinically meaningful.
Approval is only the first hurdle. With high treatment costs and safety concerns, payers and health technology assessment (HTA) bodies demand robust efficacy signals that translate to meaningful patient outcomes, well-characterized safety data, representative population data, and clear economic value before granting favorable reimbursement.
In this environment, trial execution quality provides a competitive advantage. High-quality trials produce defensible evidence that survives regulatory review, clear efficacy/safety signals for approval, real-world data payers need, competitive differentiation, and efficient trial timelines.
Unique challenges to achieving research quality in neurodegenerative disease trials
Neurodegenerative disease trials present specific operational demands that determine whether sites can deliver the data required for regulatory approval and payer negotiations.
Assessment and measurement complexity
Neurodegenerative trials often rely on subjective, clinician-rated cognitive and functional assessments. In these assessments, different raters may score the same patient performance differently, introducing noise that obscures treatment effects. In addition, validated assessments require formal training and ongoing certification, with the need for raters to maintain consistency throughout multi-year trials.
Biomarker and imaging demands
Trials are increasingly incorporating biomarkers (e.g., CSF, plasma phospho-tau, neurofilament light) and advanced imaging (e.g., amyloid PET, tau PET, volumetric MRI, ARIA monitoring). These require specialized collection procedures, strict handling protocols, certified imaging centers, and trained technical staff. Pre-analytical variability in sample handling or small variations in imaging acquisition can compromise data quality.
Safety monitoring intensity
Anti-amyloid therapies can cause ARIA, requiring serial MRI monitoring with rapid clinical correlation and dosing decisions. Biologics may cause infusion reactions, requiring trained infusion nurses and emergency preparedness. Intricate safety algorithms rely on clinical expertise in CNS disorders to exercise appropriate judgment.
Patient population realities
Narrow eligibility criteria (e.g., biomarker-confirmed diagnosis, specific cognitive ranges) shrink the participant population. In addition, trial durations of at least 18-24 months challenge retention in populations experiencing cognitive decline, while dropouts threaten statistical power. Older adult patients with mobility limitations require geographic accessibility and caregiver engagement.
Unique challenges for high-quality trial execution
Several operational realities separate trials for neurodegenerative conditions from typical studies:
- Subjective assessments: Clinician-rated cognitive and functional scales are prone to inter-rater variability, requiring formal training and ongoing certification to maintain consistency over multi-year trials.
- Biomarkers and imaging: CSF and plasma biomarkers, amyloid/tau PET, and volumetric MRI all require specialized handling and certified imaging centers because small variations can compromise data.
- Intensive safety monitoring: ARIA risk with anti-amyloid drugs, infusion reactions with biologics, and complex safety algorithms all demand CNS-specific clinical judgment.
- Recruitment and retention: Narrow biomarker-based eligibility criteria shrink the eligible population, while long trial durations and cognitive decline threaten retention, especially among mobility-limited older patients.
Strategic advantages of a site network with CNS specialists
Selecting the right research partners in neurodegenerative disease drug development requires understanding how site capabilities translate into trial outcomes.
Scientific expertise. Networks with embedded CNS specialization give sponsors access to neurologists and geriatricians, many of whom are key opinion leaders (KOLs) in their fields, experienced in the nuanced assessments these trials require. Structured training and peer-to-peer learning across the network reduce assessment variability and help sites troubleshoot protocol issues in real time.
Protocol readiness. Experienced sites arrive equipped for CSF collection, plasma biomarker chain of custody, and imaging coordination with CROs and central readers, plus quality control across sites and timepoints. Safety expertise means staff already know how to monitor and manage ARIA, run infusion suites, and execute REMS-level risk mitigation. This results in fewer screen failures, cleaner endpoint data, and fewer protocol deviations.
Operational speed. Centralized contracting, established eSource infrastructure, and standardized SOPs mean faster startup, consistent multi-site rollout, and inspection-ready data, without sacrificing quality as enrollment scales.
Recruitment reach. Sites with CNS experience typically have established referral relationships with local neurologists and primary care physicians plus community outreach that builds trust and improves referral quality. Network-wide geographic distribution gives sponsors access to diverse, pre-screened patient populations, reducing screen failures and speeding enrollment.
Participant-centered support. Flexible scheduling, transportation assistance, and caregiver support improve participant satisfaction and retention, which are both essential for reliable long-term data.
Preparing for future trends in neurodegenerative disease research
As precision medicine and biomarker-driven therapies gain momentum, site networks with CNS specialization that are investing in genetic and molecular profiling capabilities will be best positioned to support the next generation of treatments.
For smaller biotechs, this expertise pays off early. This can help inform trial design, endpoint selection, and realistic recruitment timelines, with scalable support that grows alongside the sponsor's program.
Maximizing trial success through strategic site selection
Site selection is a strategic decision with measurable consequences for speed, risk, and the strength of evidence that regulators and payers will scrutinize. Sponsors who partner with integrated, CNS-specialized site networks are better positioned to navigate complexity and get promising therapies to patients faster.
About the Author
Dr. Scott Losk is Principal Investigator (PI) at Summit Research, part of the Headlands Research network.
Dr. Losk has served as PI for 90 clinical trials focused on Alzheimer’s disease and other dementias, contributing to research on every FDA-approved Alzheimer’s therapy currently available. He has also been a sub-investigator in more than 125 trials across a wide range of central nervous system conditions, including depression, anxiety disorders, ADHD, bipolar disorder, schizophrenia, migraine, and fibromyalgia.
Deeply involved in the Alzheimer’s community, Dr. Losk regularly provides education and presentations to caregivers, clinicians, and community groups. His extensive expertise and long-standing industry relationships give him unique access to the latest research opportunities in cognitive disorders.